

PROGRAM

III DRUG R&D

OCTOBER 26-28, 2026 | PARIS, FRANCE



Millennium Hotel Paris Charles de Gaulle


2 Allée du Verger, 95700 Roissy-en-France

www.d-rnd.com/paris



2026 CO-IN

Summits World Wide



Scientific Program Overview

DAY	DATE	FORMAT	SCHEDULE
Day 1	Monday, October 26, 2026	In-Person	09:00 AM – 15:40 PM
Day 2	Tuesday, October 27, 2026	In-Person	09:00 AM – 16:30 PM
Day 3	Wednesday, October 28, 2026	Virtual	11:50 AM – 17:20 PM


Zoom Links

Join Zoom Meeting

<https://us06web.zoom.us/j/81388287424?pwd=hTDQMuzdaMyqxLVbISPMAc8bOA0Aab.1>

Meeting ID: 813 8828 7424

Passcode: 568462



08:20-08:50 Registrations & Badge Pickup
08:50-09:00 Introduction & Welcome Remarks

Keynote Presentations

Moderator: Richard B. Meagher, Professor, University of Georgia, Athens, GA



Sangwook Wu, CEO of PharmCADD, South Korea

09:00-09:45

PharmulatorTM: A Next-Generation AI/Physics, and Quantum Algorithm-Integrated Platform for Drug Discovery

Sangwook Wu is a Professor in the Department of Physics and Director of the Quantum/AI Institute at Pukyong National University. He is also the CEO and co-founder of PharmCADD, an AI- and physics-driven drug discovery company developing innovative therapeutics through its Pharmulator platform. His work integrates protein structure prediction, molecular dynamics, quantum calculations, and AI-based drug generation, with notable progress including Korea's first COVID-19 mRNA vaccine candidate to reach clinical trials.



Bilada Bilican, Sr. Director, Astrazeneca, Sweden

09:45-10:30

Discovering Causal Human Biology at Scale: Cellular Models for Target Discovery and Validation

Bilada Bilican holds a PhD in Molecular Biology from the University of London (2000–2004). He worked as a Postdoctoral Research Fellow at the University of Cambridge and later at the MRC Centre for Regenerative Medicine, University of Edinburgh. His research focuses on generating specific neuronal subtypes from pluripotent stem cells, neural stem cell lineage restriction, and protein homeostasis in human stem cell-derived neurons. His work aims to provide mechanistic insights into protein-aggregation diseases.



Ruth Roberts, Director & Co-founder, Apconix, UK

10:30-11:15

Making Safety Part of Drug Design

Professor Ruth Roberts is Chair and Director of Drug Discovery at the University of Birmingham and Co-founder of Apconix, an integrated toxicology and ion channel research company. A renowned toxicologist with over 180 peer-reviewed publications, she has received numerous prestigious awards, including the 2026 SOT Merit Award and BTS Paton Prize. Her research focuses on developing innovative models for drug discovery and development.



Coffee & Networking (11:15-11:35)

@Gallery

Oral Presentations

Track-1

Chair: Vetrivelan Subramaniyan, Professor, Sunway University, Malaysia

11:35-12:00 **Richard B. Meagher**, Professor, University of Georgia, Athens, GA
DectiSomes are Targeted Broad-Spectrum Antifungal Drugs

12:00-12:25 **Abdelnaby Khalyfa**, Professor, Marshall University, Huntington, WV
Extracellular Vesicles, Senescence, and Cardiometabolic Dysfunction in Sleep Apnea

12:25-12:50 **Eleonora Maceroni**, Researcher, University of L'Aquila, Italy
Pharmacologically Responsive *in-vitro* Platforms for Translational Antiangiogenic Drug Discovery



Group Photo & Lunch (12:50-13:50)

@Restaurant

13:50-14:15	Robert Hahn , Professor, Karolinska Institutet, Sweden Dilution Kinetics
14:15-14:40	Paul Proost , Vice-Dean & Professor, KU Leuven, Rega Institute, Belgium Preclinical Reduction of the Hyperinflammatory Response and Restoration of Lung Function in Microbial Pneumonia
14:40-15:05	Vetriselvan Subramaniyan , Professor, Sunway University, Malaysia Targeted Therapeutics in Obesity: Integrating Radiological and Molecular Phenotyping
15:05-15:30	Victoria Freund , Head of Chemistry Cluster, Fresenius University of Applied Sciences, Germany Beyond AI Hype: Understanding Innovation Diffusion in Pharmaceutical R&D
	Coffee & Networking (15:30-15:40) @Gallery
15:40-16:05	Elena Donici , Associate Professor, Nicolae Testemitanu State University of Medicine and Pharmacy, Moldova Development of an HPLC Method for the Determination of Nimesulide in Bilosomal Novesicles for Topical Drug Delivery
16:05-16:30	Laszlo Fusti-Molnar , Founder, Quantum Future Scientific Software LLC Buda, TX Toward Safer and More Accurate Virtual Screening: Integrating Low Predicted Toxicity with Improved Binding Affinity Prediction
16:30-16:55	Marta Sofia Scenna , Researcher, University of L'Aquila, Italy Modulating Cellular Dynamics and E/I Balance in ASD Models: Cellular and Neurochemical Rescue via Neurotrophin Administration
16:55-17:20	Adib Zendedel , Researcher, University of Basel, Switzerland Poster Indomethacin Increased Astrocyte-Derived miR-27b-3p-Enriched Anti-Inflammatory Exosomes and Reduced the Redox-Induced NF- κ B/PGE2/TNF- α Response

End of Day-1

Keynote Presentation

Chair: Thomas Blackburn, Founder & CEO, TPBioVentures LLC, UK**Victoire de Margerie**, Founder & CEO, Rondol Industrie, France

09:00-09:45

Hot Melt Extrusion beyond Drug Formulation: AI, Reactive Extrusion and Nutraceuticals

Victoire de Margerie founded Rondol Industrie in 2012, specializing in micro-scale pharmaceutical manufacturing technology. With over 35 years of international industry experience, she has expertise in business leadership, corporate strategy, and global communications. She has held leadership roles at Airbus and Dassault Systèmes and actively supports inclusion and education initiatives.

Oral Presentations

Track-2

09:45-10:10 **Amin Li**, Vice President-Medicinal Chemistry, Jacobio Pharma, China
The Evolution of (K)RAS Inhibitors, from Small Molecule to ADC

10:10-10:35 **Sebastian Oltean**, Associate Professor, University of Exeter, UK
Modulation of Alternative Splicing as a Novel Therapeutic Avenue in Cancer

10:35-11:00 **Md. Jashim Uddin**, Associate Professor, Vanderbilt University, Nashville, TN
Discovery of COX-2–Targeted Nanobodies for Optical Imaging of Colorectal Adenomas

**Coffee & Networking (11:00–11:15)**

@Gallery

Chair: Paul Proost, Vice-Dean & Professor, KU Leuven, Rega Institute, Belgium

11:15-11:40 **Amit Sachdeva**, Associate Professor, University of East Anglia, UK
Turning on Antibodies with Light

11:40-12:05 **Oliver Zerbe**, Professor, University of Zurich, Switzerland
Macrocyclic Peptides as Disrupters of Protein-protein Interactions and Antibiotics Against Multi-resistant Gram-negative Bacteria

12:05-12:30 **Thomas Blackburn**, Founder & CEO, TPBioVentures LLC, UK
Therapeutic Modalities and RNA Interference Technology

12:30-12:55 **Eugene Krissinel**, CCP4 Group Leader & Scientist, UKRI-STFC CCP4, UK
How Well is your Ligand Placed? An Information-Theoretic Approach to Ligand Fitting Assessment

**Lunch (12:55–14:00)**

@Restaurant

14:00-14:25 **Georg Voelcker**, Research Associate, Goethe University Frankfurt, Germany
Apoptosis Activation in Tumor Cells Using Novel Cyclophosphamides

14:25-14:50 **Frederik Rosenbaek**, Researcher, University of Southern Denmark, Denmark
Patients' Experiences with the use of Medicinal Cannabis – An International Overview and Findings from the Danish Medicinal Cannabis Pilot Program

14:50-15:15 **Phelelisiwe Dube**, Post Doctoral Fellow, North-West University, South Africa
Quinolones: Synthesis, *In-vitro* Antimicrobial Evaluation, ADME, SAR, and MOA

15:15-15:40 **Murali M. Yallapu**, Associate Professor, The University of Texas Rio Grande Valley, Edinburg, TX

End of Day-2

Join Zoom Meeting

<https://us06web.zoom.us/j/81388287424?pwd=hTDQMuzdaMyqxLVblSPMaC8bOA0Aab.1>

Meeting ID: 813 8828 7424

Passcode: 568462

11:20-11:35 Introduction

Oral Presentations

Track-3

- 12:00-12:25 Asita Elengoe**, Head of the Biotechnology Department, Lincoln University College, Malaysia
Artificial Intelligence and Structure-Based Drug Design for Hypertension: Current Advances and Future Perspectives
- 12:00-12:25 Shigeru Amano**, Researcher, Meikai University School of Dentistry, Japan
A Startup Developing a Drug Discovery Platform that Precisely Controls Nuclear Delivery to Cancer Cells Based on the Cancer-selective Nuclear-targeting Peptide csNTP
- 12:25-12:50 Liga Petersone**, Lead Researcher, Rīga Stradiņš University, Latvia
Characterisation and Evaluation of Japanese Quince Pectin as a Natural Carrier for Drug Delivery Systems

Keynote Presentations

**Hans Jorg Schneider**, Professor, Saarland University, Germany

12:50–13:35

The Experimental Quantification of Intermolecular Noncovalent Interactions – Strategies and Limitations

Professor Hans-Jörg Schneider is renowned for his pioneering contributions to supramolecular chemistry, particularly molecular recognition and host–guest interactions. His research advances cyclodextrin and cyclophane chemistry, synthetic enzyme and receptor models, and reaction mechanisms studied through NMR spectroscopy. With approximately 300 scientific publications, he has made significant contributions to understanding molecular interactions and designing functional supramolecular systems.

**David J Greenblatt**, Professor, Tufts University, Boston, MA

13:35–14:20

Volume of Distribution of Drugs: What Does It Mean, and Why Does It Matter?

Dr. David J. Greenblatt is a distinguished clinical pharmacologist and Professor at Tufts University School of Medicine. His research focuses on pharmacokinetics, drug metabolism, and drug–drug interactions. He has made significant contributions to understanding how medications interact with foods, herbal products, and other drugs. With decades of research experience and extensive scientific publications, he has helped advance clinical pharmacology and the safe and effective use of medicines.

**Coffee & Networking (14:20-14:30)****Maria Kontoyianni**, Professor, Southern Illinois University Edwardsville, Edwardsville, IL

14:30-15:15

An Integrated Approach toward Somatostatin-subtype 4 Agonism

Dr. Maria Kontoyianni is a Professor of Pharmaceutical Sciences at Southern Illinois University Edwardsville. Her research focuses on computational chemistry, computer-aided drug discovery, molecular docking, and virtual screening. She contributes to developing innovative computational approaches for identifying promising therapeutic compounds and advancing drug discovery.

Oral Presentations

Track-4

- 15:15–15:40 George Uhl**, Professor, University of Maryland School of Medicine, Baltimore, MD
PTPRD PAM Development for Alzheimer's Disease Neurofibrillary Pathology

- | | |
|-------------|--|
| 15:40–16:05 | Hideaki Yano , Assistant Professor, Northeastern University, Boston, MA
Functional Selectivity of Dopamine D1 Receptor Positive Allosteric Modulators |
| 16:05–16:30 | Rana Rais , Associate Professor, The Johns Hopkins University, Baltimore, MD
Brain Delivery of nSMase2 Inhibitor Using Prodrug Approaches and Dendrimer Nanoparticle Systems |
| 16:30–16:55 | Romi Gupta , Associate Professor, The University of Alabama at Birmingham, Birmingham, AL
ATAD2 is a Novel Epigenetic Therapeutic Target for Melanoma Drug Development |
| 16:55–17:20 | Lisa Ricciardi , President and CEO, Cognition Therapeutics, Purchase, NY
From Lab Bench to Pivotal Trial: One CEO's experience |
| 17:20–17:45 | Subhash Chauhan , Professor, The University of Texas Rio Grande Valley, McAllen, TX
Novel Therapeutic Strategies for Pancreatic Cancer |

End of Day-3

REMINDERS

[illegible]

SAVE THE DATES

Next Edition of

IV DRUG R&D



February 21-23, 2028



Boston, MA



Organized By



CO-IN Symposia LLC

 <https://d-rnd.com/paris>

 # 5900 Balcones Dr Suit 100, Austin, TX 78731

 +1-512-270-2990

 heidi@d-rnd.com; heidi@coinsymposia.org